PTPRC and neoplasm: Another study using GL261 and xenograft GBM models showed that systemic administration of anti-CCL2 antibodies resulted in significant reduction of both CD45+CD11b+ and CD11+Gr1+ myeloid cells and modestly increased the survival time of tumor-bearing mice, while remarkable anticancer efficacy was achieved when anti-CCL2 antibodies were combined with TMZ (124).